Here is why Pfizer can't seem to get off the mat and whether it's worth buying the dip on today. I won't rehash Pfizer's pandemic journey too much. The company developed and sold a vaccine (Comirnaty) ...

Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

The stock's fall snapped a four-day winning streak.

For Pfizer, the consensus sales estimate for the current quarter of $17.5 billion indicates a year-over-year change of +22.8%. For the current and next fiscal years, $63.36 billion and $62.98 ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals ...

Pfizer (NYSE:PFE) recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...